

Generic Drug Savings in Connecticut



Medicaid:	\$449 million
Medicare:	\$754 million
Cash (Non-Insured)	\$134 million
Commercial Insured:	\$1.3 billion
Total	\$2.6 billion

Generic medicines drive savings, not costs. Generics saved Connecticut **\$2.6 billion in 2015**, according to the 2016 Generic Drug Savings & Access in the United States report compiled by the QuintilesIMS Institute on behalf of the Generic Pharmaceutical Association (GPhA).

Generic drug manufacturers are true drivers of health system value – enabling access to safe and effective generic medicines for patients, public programs, taxpayers, employers and others. GPhA welcomes the chance to work with policymakers, regulators and stakeholders to increase generic competition and expand patient access to more affordable medicines.

Generic Drug Savings in the U.S.



Generics are 89% of Prescriptions Dispensed but only 27% of Total Drug Costs

Medicare Savings:



\$67.6 B



\$1,737
Per Enrollee

Medicaid Savings:



\$32.7 B



\$450
Per Enrollee

\$227 Billion



Total Savings in 2015

\$1.46 Trillion



10-Year Savings (2006-2015)

Visit www.rxolutions.us for more information.

